Shine-On Biomedical Co., Ltd., a new drug development company for "next-generation anti-cancer drugs", was established in April 2021. It has a number of novel patented antibody drug development technology platforms. A number of professional doctoral and master R&D teams and consultants with medical backgrounds at home and abroad are committed to the development of novel and effective multispecific antibody drugs and nucleic acid therapeutic drugs with the best cancer treatment strategy for patients as the core.
We have three novel drug development platforms:
1. Tri-specific T cell engager: Based on nanobody, a tri-specific target antibody is developed, which can simultaneously bind to the immune checkpoints of tumor cells and T cells, increasing the tumor cytotoxicity. In addition, this antibody has an Fc domain and can also bind to immune cells such as neutrophils and eosinophils, thereby promoting the killing ability of immune cells induced by the antibody.
2. T & NK cell engager: Based on scFv antibody, a trispecific target antibody has been developed, which can simultaneously bind tumor cells, T cells and NK cells, and increase the tumor cytotoxicity.
3. Exosomal nucleic acid drug: The use of exosomes as the carrier of nucleic acid drugs solves the weakness that nucleic acid drugs cannot directly enter tumor cells and are easily degraded. Exosomes are secreted by cells and are less toxic than liposomes. In addition, the exosomal nucleic acid drugs developed by this platform can also be loaded with chemotherapeutic drugs, and have nanobody on surface, which have the function of targeted therapy.